Management of Rare Ovarian Cancer Histologies
Authors:
- 20 September 2019
- journal article
- review article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 37 (27) , 2406-2415
Abstract
No abstract availableThis publication has 74 references indexed in Scilit:
- BRAF Mutation is associated with early stage disease and improved outcome in patients with low‐grade serous ovarian cancerCancer, 2012
- Clear cell carcinoma of the ovary: Is there a role of histology-specific treatment?Journal of Experimental & Clinical Cancer Research, 2012
- Rare cancers are not so rare: The rare cancer burden in EuropeEuropean Journal of Cancer, 2011
- Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesisPathology, 2011
- ARID1AMutations in Endometriosis-Associated Ovarian CarcinomasNew England Journal of Medicine, 2010
- BRAF Mutation Is Rare in Advanced-Stage Low-Grade Ovarian Serous CarcinomasThe American Journal of Pathology, 2010
- Advanced stage mucinous adenocarcinoma of the ovary is both rare and highly lethalCancer, 2010
- Mucinous advanced epithelial ovarian carcinoma: clinical presentation and sensitivity to platinum–paclitaxel-based chemotherapy, the GINECO experienceAnnals of Oncology, 2010
- Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical stagingBritish Journal of Cancer, 2006
- The Activity of Taxanes in the Treatment of Sex Cord-Stromal Ovarian TumorsJournal of Clinical Oncology, 2004